NCT00269217View on ClinicalTrials.gov

Lipid Efficacy Study (0524B-022)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,400

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Primary HypercholesterolemiaMixed Hyperlipidemia
Interventions
DRUG

niacin (+) laropiprant (+) simvastatin

Duration of Treatment 12 Weeks

DRUG

Comparator: niacin (+) laropiprant

Duration of Treatment 12 Weeks

DRUG

Comparator: simvastatin

Duration of Treatment 12 Weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00269217 - Lipid Efficacy Study (0524B-022)(COMPLETED) | Biotech Hunter | Biotech Hunter